Predicted to contribute to cytochrome-c oxidase activity. Involved in several processes, including lactation; positive regulation of cellular biosynthetic process; and positive regulation of necrotic cell death. Predicted to localize to the mitochondrial inner membrane and respiratory chain complex IV. Biomarker of type 2 diabetes mellitus. Orthologous to human MT-CO2 (mitochondrially encoded cytochrome c oxidase II); INTERACTS WITH 17alpha-ethynylestradiol; 2,2',4,4'-Tetrabromodiphenyl ether; atrazine.
Co2; COII; Cox2; cytochrome c oxidase 2, mitochondrial; cytochrome c oxidase II, mitochondrial; cytochrome c oxidase subunit 2; cytochrome c oxidase subunit II
[Catechin co-treated with Zymosan] results in decreased expression of COX2 protein, Catechin promotes the reaction [Zymosan results in increased expression of COX2 protein]
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein], ARNTL protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]]
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein], ARNTL protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]]
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of COX2 mRNA
[Chlorogenic Acid co-treated with Zymosan] results in decreased expression of COX2 protein, Chlorogenic Acid inhibits the reaction [Zymosan results in increased expression of COX2 protein]
[caffeic acid co-treated with Zymosan] results in increased expression of COX2 protein, caffeic acid inhibits the reaction [Zymosan results in increased expression of COX2 protein]
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of COX2 mRNA
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein], ARNTL protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]]
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein], ARNTL protein affects the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]]
[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein] more ...
ARNTL protein affects the reaction [Polyphenols inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]], Polyphenols inhibits the reaction [Hydrogen Peroxide results in decreased expression of COX2 protein]
[licarin A affects the susceptibility to [INS protein co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone]] which results in increased expression of COX2 mRNA
Butylated Hydroxyanisole inhibits the reaction [Reactive Oxygen Species results in decreased expression of COX2 protein], Butylated Hydroxytoluene inhibits the reaction [Reactive Oxygen Species results in decreased expression of COX2 protein]
[caffeic acid co-treated with Zymosan] results in increased expression of COX2 protein, caffeic acid inhibits the reaction [Zymosan results in increased expression of COX2 protein]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin